Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age ≥18 years
ECOG Performance Status ≤ 1.
Estimated life expectancy of at least 12-weeks;
Measurable disease as per RECIST guideline (Version 1.1);
Any malignancy within past 5-years, except non-melanoma skin cancer, cervical intraepithelial neoplasia, or in situ cervical cancer
Known hypersensitivity to the study drugs
Treatment with any anti-cancer agents within 28 days of study entry
Presence of clinically evident active CNS metastases, including leptomeningeal involvement, requiring steroid or radiation therapy